Skip to content
News
Our Chief Commercial Officer, Jordi Robinson, was recently asked to contribute his thoughts to an article in CHEManager about the evolution of the CDMO industry (particularly how it has changed post-COVID). The article features a diverse range of views but there are several common themes throughout, such as sustainability, the value of partnerships and supply chain resilience – all subjects which we at Navin Molecular consider critical to the future success of our business.
https://www.chemanager-online.com/en/news/evolution-cdmo-industry-0
Our CEO, Rajendra Kumar Sahu, was recently interviewed by Manufacturing Chemist about the current state of the CDMO market in India, a subject that’s generating a lot of interest these days, particularly due to the potential impact of the BIOSECURE act’s recent passing in the US House of Representatives.
https://www.manufacturingchemist.com/cost-compliance-and-quality-the-benefits-of-outsourcing
In just over two weeks, CPhI Worldwide will open its doors in Milan, and we will be there as always! We are excited to announce Navin Molecular’s participation at the show. As a leading CDMO, we’re eager to showcase our cutting-edge solutions and discuss how we can help bring your innovations into the clinic.
If you want to learn more about the technologies and capabilities we have in small molecules, which cover the entire product life cycle from development through to commercial cGMP manufacturing, please stop by our stand (7F14) where you can meet with the commercial team and our CEO, Rajendra Kumar Sahu, and discover how we can accelerate your project from concept to commercial production!
Our Chief Commercial Officer, Jordi Robinson, was recently asked to contribute to Pharma’s Almanac’s roundtable discussion, this time on the subject of the advancements in technology and their effect on the capabilities of CDMOs to support the drug development cycle. Along with a number of Navin Molecular’s peers from across the industry, Jordi gave his thoughts on how a broad technology platform is becoming increasingly important for CDMOs wanting to establish themselves as true partners.
Register for free at pharmasalmanac.com to read the full article (and have access to other content).
https://www.pharmasalmanac.com/articles/how-are-advancements-in-technology-reshaping-the-roles-and-capabilities-of-cdmos-and-cros-in-the-drug-development-life-cycle
Our CCO recently took part in a wide-ranging discussion on current trends in raw material and API intermediate sourcing. The link to the full article is below:
https://www.pharmtech.com/view/diversifying-the-supply-of-raw-materials
12 July 2024
Following the announcement of the construction of our new “GMP-4” manufacturing facility, the story was featured in a number of industry publications. The below links have more details.
As you know, Google ranks websites partly based on the number of links to that site, so I think adding all of the below will help our search engine ranking.
https://www.pharmoutsourcing.com/1315-News/613867-Navin-Molecular-to-Invest-up-to-35M-to-Expand-GMP-Manufacturing-Capabilities/?catid=6263
https://manufacturingchemist.com/navin-molecular-to-invest-up-to-35-million
https://www.biospectrumindia.com/news/97/24863/navin-molecular-to-invest-35-m-for-expanding-manufacturing-capabilities.html
https://biovoicenews.com/navin-molecular-invests-35-million-to-expand-gmp-manufacturing-capabilities/
https://www.chemanager-online.com/en/news/navin-molecular-plans-eu326-million-expansion-gmp-manufacturing
https://www.echemi.com/cms/1958679.html
https://www.lskh.digital/news/navin-molecular-to-invest-up-to-35-million-to-expand-gmp-manufacturing-capabilities/
https://drug-dev.com/navin-molecular-to-invest-up-to-35-million-to-expand-gmp-manufacturing-capabilities/
https://chemicalweekly.com/news/latestnews/article/632
12 July 2024
Our CCO Jordi Robinson was recently interviewed by Contract Pharma and asked “What are “3 Key Trends” shaping the CDMO industry in 2024 and beyond?”
You can read his thoughts by following the below link. Let us know on our LinkedIn page (https://www.linkedin.com/company/navin-molecular-cdmo) if you agree with Jordi’s thoughts on the future of the CDMO industry.
27 June 2024
Our CCO Jordi Robinson recently sat down with Pharmtech.com as part of their regular “Drug Digest” video series. In a wide-ranging interview, which starts around 27.50, Jordi was asked his opinions on the major changes in the outsourcing landscape in the last few years, including – but not limited – to the current impact the Biosecure act is having on the industry’s attitude to outsourcing.
Access the video here
19 June 2024
Navin Fluorine Board approves Rs 288 Cr (approx. USD 35M) capital investment for the construction of cGMP-4 at our Dewas facility to add additional 200kL multi-purpose capacity.
6 February 2024
